197 related articles for article (PubMed ID: 20501635)
1. Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.
Ait-Oudhia S; Scherrmann JM; Krzyzanski W
J Pharmacol Exp Ther; 2010 Sep; 334(3):897-910. PubMed ID: 20501635
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.
Woo S; Krzyzanski W; Jusko WJ
J Pharmacol Exp Ther; 2006 Dec; 319(3):1297-306. PubMed ID: 16973883
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.
Ramakrishnan R; Cheung WK; Wacholtz MC; Minton N; Jusko WJ
J Clin Pharmacol; 2004 Sep; 44(9):991-1002. PubMed ID: 15317827
[TBL] [Abstract][Full Text] [Related]
4. Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.
Krzyzanski W; Perez-Ruixo JJ; Vermeulen A
J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):349-77. PubMed ID: 18551354
[TBL] [Abstract][Full Text] [Related]
5. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin.
Woo S; Jusko WJ
Drug Metab Dispos; 2007 Sep; 35(9):1672-8. PubMed ID: 17576810
[TBL] [Abstract][Full Text] [Related]
6. Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits.
Reynaldo-Fernández G; Solozábal J; Amaro D; Fernández-Sánchez EM; Rodríguez-Vera L; Bermejo M; Mangas-Sanjuan V; Troconiz IF
Eur J Pharm Sci; 2018 Jul; 120():123-132. PubMed ID: 29729414
[TBL] [Abstract][Full Text] [Related]
7. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).
Woo S; Krzyzanski W; Jusko WJ
J Pharmacokinet Pharmacodyn; 2007 Dec; 34(6):849-68. PubMed ID: 17943422
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in rats.
Kato M; Okano K; Sakamoto Y; Miura K; Uchimura T; Saito K
Arzneimittelforschung; 2001 Jan; 51(1):91-5. PubMed ID: 11215332
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly.
Cheung W; Minton N; Gunawardena K
Eur J Clin Pharmacol; 2001 Aug; 57(5):411-8. PubMed ID: 11599659
[TBL] [Abstract][Full Text] [Related]
10. A quantitative systems pharmacology model of hyporesponsiveness to erythropoietin in rats.
Nguyen LM; Li Z; Yan X; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):687-710. PubMed ID: 34100188
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent clearance and hematological pharmacodynamics upon erythropoietin multiple dosing in rats.
Ait-Oudhia S; Scherrmann JM; Krzyzanski W
Biopharm Drug Dispos; 2010 Jul; 31(5-6):298-315. PubMed ID: 20578212
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects.
Pérez-Ruixo JJ; Krzyzanski W; Bouman-Thio E; Miller B; Jang H; Bai SA; Zhou H; Yohrling J; Cohen A; Burggraaf J; Franson K; Davis HM
Clin Pharmacokinet; 2009; 48(9):601-13. PubMed ID: 19725594
[TBL] [Abstract][Full Text] [Related]
13. Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep.
Freise KJ; Widness JA; Schmidt RL; Veng-Pedersen P
J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):285-323. PubMed ID: 18553126
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys.
Ramakrishnan R; Cheung WK; Farrell F; Joffee L; Jusko WJ
J Pharmacol Exp Ther; 2003 Jul; 306(1):324-31. PubMed ID: 12676891
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and haematological parameters of recombinant human erythropoietin after subcutaneous administrations in horses.
Souillard A; Audran M; Bressolle F; Jaussaud P; Gareau R
Biopharm Drug Dispos; 1996 Dec; 17(9):805-15. PubMed ID: 8968532
[TBL] [Abstract][Full Text] [Related]
16. An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects.
Krzyzanski W; Perez-Ruixo JJ
Pharm Res; 2007 Apr; 24(4):758-72. PubMed ID: 17318417
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers.
Krzyzanski W; Wyska E
Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):637-45. PubMed ID: 18071675
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human granulocyte colony-stimulating factor increases circulating burst forming unit-erythron and red blood cell production in patients with severe human immunodeficiency virus infection.
Miles SA; Mitsuyasu RT; Lee K; Moreno J; Alton K; Egrie JC; Souza L; Glaspy JA
Blood; 1990 Jun; 75(11):2137-42. PubMed ID: 1693297
[TBL] [Abstract][Full Text] [Related]
19. Proof-of-concept study on improved efficacy of rHuEPO administered as a long-term infusion in rats.
Szczesny D; Mołoniewicz K; Markuszewski MJ; Wiczling P
Pharmacol Rep; 2020 Oct; 72(5):1264-1270. PubMed ID: 32748255
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin.
Xenocostas A; Cheung WK; Farrell F; Zakszewski C; Kelley M; Lutynski A; Crump M; Lipton JH; Kiss TL; Lau CY; Messner HA
Eur J Clin Pharmacol; 2005 May; 61(3):189-95. PubMed ID: 15776276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
